Background: Over the last three decades, monoclonal antibodies (MAbs) have made a striking transformation from scientific tools to powerful human therapeutics. Muromonab CD3 a murine MAb was the first FDA approved therapeutic MAb for the prevention of kidney transplant rejection. Since its approval in 1986, there has been a decline in further application and approvals until the late 1990s when the first chimeric Mab, Rituximab was approved for the treatment of lowgrade B cell lymphoma in 1997. With the approval by licensing authorities of chimeric, followed by humanized and then fully human monoclonal antibodies, the rate of approval and monoclonal antibodies available in the market for the treatment of various diseases has increased dramatically. As of March 2017, FDA has approved approximately 60 therapeutic MAbs which are currently under evaluation in various phases of clinical trials.
Objective: MAbs are approved for the treatment of diseases belonging to various systems like cardiovascular, respiratory, hematology, kidney, immunology and oncology. MAbs are approved for the treatment of orphan diseases or indications such as paroxysmal nocturnal hemoglobinuria as well as cancers and multiple sclerosis where hundreds of patients are treated and even diseases such as breast cancer, asthma and rheumatoid arthritis where millions are being treated. This review focuses briefly on types, molecular targets, mechanism of actions and therapeutic indications of FDA approved MAb products that are currently available in the market.
Conclusion: With the advent of fully human MAbs, the efficacy and safety have improved in the treatment of various cardiovascular, cancer, respiratory, hematology, autoimmune diseases and infections. The introduction of biosimilars will increase the affordability and utilization of MAbs in the treatment of various diseases.
Keywords: Monoclonal antibody, cancer, autoimmune, transplant, cytokines, growth factors.
Differentiation of Glioblastoma and Lymphoma Using Feature Extraction and Support Vector Machine
CNS & Neurological Disorders - Drug Targets Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking
Combinatorial Chemistry & High Throughput Screening Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Current Cancer Drug Targets Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Photochemotherapy in the Treatment of Cancer
Current Medicinal Chemistry Serum Proteomics in the Diagnosis and Treatment of Haematological Malignancies
Current Proteomics Molecular Cloning of a Novel PPEF-1 Gene Variant from a T-Cell Lymphoblastic Lymphoma Cell Line
Recent Patents on DNA & Gene Sequences (DIscontinued) Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry HPMA Copolymer-Bound Doxorubicin Induces Immunogenic Tumor Cell Death
Current Medicinal Chemistry Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy
Current Pharmaceutical Biotechnology Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Autoimmune Lymphoproliferative Syndrome (ALPS)
Current Pharmaceutical Design Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy
Current Cancer Drug Targets Impact of PET on the Radiation Treatment of Hodgkins Lymphoma
Current Radiopharmaceuticals The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Current Drug Targets Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers
Current Drug Targets EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?